Jorge A. Gallardo-Cartagena

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

Raphael J. Landovitz, Deborah Donnell, Meredith E. Clement et al. · New England Journal of Medicine · 2021 · 853 citations · Full text

Public Health, Infectious Diseases, Pharmacotherapy +16

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons

Colleen F. Kelley, Maribel Acevedo-Quiñones, Allison L. Agwu et al. · New England Journal of Medicine · 2024 · 229 citations

Public Health, Pharmacology, Pharmacotherapy +17

Clinical and Immunologic Outcomes After Immediate or Deferred Antiretroviral Therapy Initiation During Primary Human Immunodeficiency Virus Infection: The <i>Sabes</i> Randomized Clinical Study

Javier R. Lama, Rachel Bender Ignacio, Ricardo Alfaro et al. · Clinical Infectious Diseases · 2020 · 26 citations · Full text

Public Health, Immunology, Infectious Diseases +16

Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody

Srilatha Edupuganti, Nyaradzo Mgodi, Shelly Karuna et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2021 · 26 citations · Full text

Public Health, Immunology, Pharmacotherapy +17

Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global region

Shelly Karuna, Jorge A. Gallardo-Cartagena, Deborah Theodore et al. · Journal of Global Health · 2023 · 19 citations · Full text

Veterinary Medicine, Health Sciences, Infectious Diseases +14